NCT06200363View on ClinicalTrials.gov

A Clinical Study of T3011 in Combination With Regorafenib in Patients With Advanced Colorectal Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

September 21, 2023

Primary Completion Date

November 30, 2024

Study Completion Date

November 30, 2024

Conditions
Advanced Colorectal Cancer
Interventions
DRUG

T3011

T3011 will be administered intravenously on D1, 4, 8, 11, 15, 18 of each 28-day cycle.

DRUG

Regorafenib

Regorafenib will be administered orally once daily for the first 21 days of each 28-day cycle according to NCCN and CSCO guidance.

Trial Locations (1)

Unknown

RECRUITING

West China Hospital, Sichuan University, Chengdu

All Listed Sponsors
lead

West China Hospital

OTHER